There has been a lot of discussion over recent years about the ways in which genetic testing may help make the treatment of depression become more targeted and effective. The theory is that genetic markers may help predict how different people are likely to respond to different drugs. This is clearly something that would interest patients and clinicians, as currently less than 50% of people with depression see their symptoms improving when they take their first antidepressant. The study was carried out by a consortium of people from academia and industry. Many drug companies were involved in the research and the sources of funding and competing interests are clearly set out in the full-text of the article.
View the original article here: Genetic tests unlikely to help improve drug treatment for depression …
